These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11353605)

  • 1. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.
    Quenelle DC; Winchester GA; Staas JK; Barrow EL; Barrow WW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1637-44. PubMed ID: 11353605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.
    Quenelle DC; Staas JK; Winchester GA; Barrow EL; Barrow WW
    Antimicrob Agents Chemother; 1999 May; 43(5):1144-51. PubMed ID: 10223927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.
    Barrow EL; Winchester GA; Staas JK; Quenelle DC; Barrow WW
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2682-9. PubMed ID: 9756777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
    Klemens SP; Cynamon MH
    Antimicrob Agents Chemother; 1996 Feb; 40(2):298-301. PubMed ID: 8834869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
    Ul-Ain Q; Sharma S; Khuller GK
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.
    Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
    Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
    Dutt M; Khuller GK
    Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
    Miyazaki E; Chaisson RE; Bishai WR
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Park SW; Tasneen R; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
    Reichman LB; Lardizabal A; Hayden CH
    Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
    Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
    Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
    Cynamon M; Sklaney MR; Shoen C
    J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
    Labana S; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.